Carrie-Anne Mathew

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

S. Delany-Moretlwe, J. Hughes, B. G. Mirembe, 2022, The Lancet.

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.

S. Delany-Moretlwe, C. Petropoulos, J. Mellors, 2022, The Journal of infectious diseases.

Cabotegravir for Prevention of HIV-1 in Women: Results From HPTN 084, a Phase III, Randomised Controlled Trial

S. Delany-Moretlwe, J. Hughes, M. Moorhouse, 2022, SSRN Electronic Journal.